Obeda: Dr. Reddy's Generic Semaglutide Guide
✓ Free to download
Learn about Obeda, Dr. Reddy's generic semaglutide in India, including how it works, pricing, dosing, and comparisons to other brands.
If your doctor has mentioned Obeda as a weight loss or diabetes treatment option, you are looking at one of the newest GLP-1 medicines to reach Indian pharmacies. Dr. Reddy's Laboratories, one of India's most trusted pharmaceutical companies, launched Obeda following the semaglutide patent expiry on March 20, 2026.
Availability update (October 2026): Dr. Reddy's paused supplies of the original Obeda injection in July 2026 after finding an impurity issue linked to the active ingredient, and said supply would not return before November. It has since started selling two new semaglutide brands, Obeda Pro and Obeda Plus. Obeda tablets (oral semaglutide) were not affected. Check current stock with your pharmacist, and do not change brand, pen or strength without your prescriber.
This guide explains what Obeda is, how it works, what it costs, and what to expect when you start it.
Important: Always consult your healthcare provider before starting any medication. This article is for informational purposes only.
What Is Obeda?
Obeda is Dr. Reddy's brand name for semaglutide: the active molecule found in Ozempic (diabetes) and Wegovy (weight loss). It belongs to a class of medicines called GLP-1 receptor agonists.
GLP-1 is a hormone your gut naturally produces after eating. It tells your brain you are full, slows stomach emptying, and prompts the pancreas to release insulin when blood sugar rises. Semaglutide mimics this hormone but lasts a full week per dose, far longer than your body's natural version.
At launch, the Obeda injection was approved by India's drug regulator (DCGI) for:
- Type 2 diabetes: improving blood sugar control alongside diet and exercise
Dr. Reddy's said it was seeking a separate approval for chronic weight management. Ask your prescriber or pharmacist what the pack you are given is approved for. Dr. Reddy's has also launched Obeda tablets (oral semaglutide, 3 mg, 7 mg and 14 mg, taken once a day) for type 2 diabetes.
Dr. Reddy's: Why It Matters Who Makes It
Dr. Reddy's Laboratories is not a small player. Founded in Hyderabad in 1984, it is one of India's largest pharmaceutical companies with a global presence and a strong track record in producing high-quality generics. Its medicines are approved by the US FDA, European EMA, and India's DCGI.
When a company like Dr. Reddy's launches a generic, it carries a level of manufacturing credibility that matters, especially for an injectable medicine like semaglutide, where consistency in formulation and sterility standards are critical.
Obeda Pricing in India
Launch prices reported in March and April 2026. Prices change, so check current prices with your pharmacist.
| Product | Manufacturer | Price (approx.) |
|---|---|---|
| Obeda (2 mg or 4 mg pen, one month) | Dr. Reddy's | ₹4,200 a month |
| Sematrinity | Sun Pharma | ₹750–₹1,300 a week |
| Semaglyn | Zydus Lifesciences | ~₹2,200 a month |
| Ozempic (0.25 mg to 1 mg pens) | Novo Nordisk | ~₹5,660–₹9,100 a pen, after the April 2026 price cut |
Obeda's launch price made semaglutide more affordable than Novo Nordisk's brands were before generics arrived. Several other Indian generic brands launched at lower prices.
How Obeda Works
Once injected, semaglutide binds to GLP-1 receptors throughout your body and produces several effects.
In your brain: Appetite signals are suppressed. Most people notice they feel full faster and have fewer cravings, especially for high-calorie, high-fat foods.
In your stomach: Digestion slows down. Food stays in your stomach longer, which prolongs the feeling of fullness after meals.
In your pancreas: Insulin release is stimulated when blood sugar rises. Glucagon (which raises blood sugar) is reduced. This two-sided action improves blood sugar control in type 2 diabetes.
Long-term weight effect: When appetite reduces and you eat less consistently over weeks and months, the body draws on stored fat for energy. This is how GLP-1 medicines produce meaningful, sustained weight loss.
Obeda Dosing: How It Works
Semaglutide is always started at a low dose and gradually increased. This slow escalation significantly reduces nausea and other side effects. Your doctor will determine the right schedule for you, but the standard approach is:
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 0.25 mg weekly | Initiation: body adjustment |
| 5 onwards | 0.5 mg weekly | Maintenance dose for many people |
| After at least 4 weeks on 0.5 mg, if needed | 1 mg weekly | Increased effect |
The 2 mg and 4 mg figures on Obeda packs are the total amount of semaglutide in each pen, not the weekly dose. The 2 mg pen gives 0.25 mg or 0.5 mg doses and the 4 mg pen gives 1 mg doses, so 1 mg weekly is the highest Obeda dose. Not everyone needs to reach 1 mg. Your doctor will decide based on your response and how well you tolerate the medicine. If you miss a dose, follow the leaflet in your pack and ask your pharmacist or doctor.
What to Expect in the First Few Weeks
Week 1–2: Most people notice some reduction in appetite. Nausea is common in the first week, usually mild and short-lived.
Week 3–4: Nausea typically eases as your body adjusts. Appetite suppression becomes more consistent.
Week 5–8: At the 0.5mg dose, many people begin noticing a meaningful change in how much they eat at each meal.
Month 3 onwards: Weight loss tends to become more noticeable. Blood sugar improvements (in those with type 2 diabetes) usually appear within the first 4–6 weeks.
In the STEP 1 trial, adults with obesity (without diabetes) taking semaglutide 2.4 mg weekly, a higher dose than Obeda provides, lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. In STEP 2, adults with type 2 diabetes taking semaglutide 1 mg lost about 7% over 68 weeks. Results vary based on diet, activity level, and individual response.
Common Side Effects
Like all GLP-1 medicines, Obeda's most common side effects are gastrointestinal:
- Nausea: most common, especially in the first few weeks
- Vomiting: less frequent, usually linked to nausea
- Diarrhoea or constipation
- Reduced appetite (this is also part of how the medicine works)
- Stomach discomfort or burping
Most of these improve within 4–6 weeks. Eating smaller meals, avoiding fatty or rich food, and staying hydrated helps manage them.
Serious but rare side effects include pancreatitis, kidney problems from dehydration, gallbladder problems, low blood sugar (mainly with insulin or sulfonylureas), worsening diabetic eye disease, and serious allergic reactions.
Get urgent medical help for severe stomach pain that does not go away (it may spread to your back, with or without vomiting), pain in the upper right abdomen with fever or yellowing of the skin or eyes, signs of a serious allergic reaction (swelling of the face or throat, trouble breathing), or vomiting or diarrhoea so severe you cannot keep fluids down. If you also take insulin or a sulfonylurea, know the signs of low blood sugar. Tell your doctor about any change in your vision if you have diabetic eye disease, and tell the team before any surgery or sedation.
Who Should Not Take Obeda
Obeda is not suitable for everyone. Semaglutide is not recommended, or needs careful discussion with your doctor, if you have:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- A previous serious allergic reaction to semaglutide
- Severe gastrointestinal disease (e.g., severe gastroparesis)
- Pregnancy, breastfeeding, or plans to become pregnant (semaglutide is usually stopped at least 2 months before a planned pregnancy)
- Type 1 diabetes: semaglutide is not approved for this condition
- A history of pancreatitis or diabetic eye disease (your doctor will weigh this)
Always disclose your full medical history and all medications to your doctor before starting Obeda.
Obeda vs Other Indian Generic Semaglutides
All Indian generic semaglutides contain the same active molecule. Here is how the key brands compare:
| Brand | Maker | Approved use at launch | Strengths |
|---|---|---|---|
| Obeda | Dr. Reddy's | Type 2 diabetes | 2 mg pen (0.25/0.5 mg doses), 4 mg pen (1 mg doses) |
| Sematrinity | Sun Pharma | Type 2 diabetes | Two strengths |
| Semaglyn | Zydus Lifesciences | Type 2 diabetes and weight management | Check the pack |
| Noveltreat | Sun Pharma | Chronic weight management | Five strengths |
Pens differ between brands, so a dose on one brand's pen does not automatically match another's. The best option depends on your diagnosis, your doctor's preference and your dose stage. Do not switch brands without your prescriber.
Tracking Your Obeda Journey
Staying consistent with a once-weekly injection, especially during dose escalation, benefits from simple tracking. Knowing which day you injected, how you felt, and whether your appetite changed week to week gives you useful information to bring to your next clinical review.
Weight Easy is designed for exactly this, tracking your GLP-1 dose cycle, logging weight changes, and noting side effects over time. It works with any brand of semaglutide, including Obeda.
Related Articles
- Obeda Price in India (2026): Full Cost Breakdown
- Who Should Take Obeda? Eligibility Guide
- Obeda Side Effects: Complete Guide
Final Takeaway
Obeda brings Dr. Reddy's manufacturing quality to a medicine, semaglutide, that has become one of the most clinically effective treatments for obesity and type 2 diabetes available today. With the semaglutide patent now expired in India, the barrier is cost and access, not chemistry.
If your doctor has prescribed Obeda or recommended it as an option, the clinical evidence behind the molecule is strong. Start at the lowest dose, follow the escalation schedule, and give it at least 12 weeks to assess the full effect.
Consult your healthcare provider before starting any medication.
Sources
- PharmEasy product listing: Obeda 2mg Pre Filled Pen. https://pharmeasy.in
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. https://doi.org/10.1056/NEJMoa2032183
- Marso SP et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM. https://doi.org/10.1056/NEJMoa1607141
- MedlinePlus, Semaglutide injection. https://medlineplus.gov/druginfo/meds/a618008.html
- Davies M et al. (2021). Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. https://doi.org/10.1016/S0140-6736(21)00213-0
- Ozempic prescribing information (FDA): https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
- Dr. Reddy's Obeda injection launch, DCGI approval for type 2 diabetes, strengths and price (BioSpectrum India, March 2026): https://biospectrumindia.com/news/16/27524/dr-reddys-laboratories-announces-launch-of-dcgi-approved-semaglutide-injection-obeda-for-type-2-diabetes.html
- Generic semaglutide launch prices and indications in India (ThePrint, March 2026): https://theprint.in/india/rs-325-4200-month-dr-reddys-sun-pharma-glenmark-kick-off-generic-semaglutide-price-war/2885525/
- Obeda injection supply pause and launch of Obeda Pro and Obeda Plus (India Weekly, October 2026): https://www.indiaweekly.biz/dr-reddys-launches-two-new-semaglutide-brands-after-obeda-injection-supply-disruption/
- Ozempic and Wegovy India price ranges after the cut (Outlook Business, March 2026): https://www.outlookbusiness.com/corporate/novo-nordisk-cuts-ozempic-wegovy-prices-by-up-to-48-amid-generic-pressure
- Apollo Pharmacy listing, Obeda 1 mg (4 mg/3 ml) pen: https://www.apollopharmacy.in/medicine/obeda-1-mg-prefilled-pen-injection-1-s
- Dr. Reddy's oral semaglutide (Obeda tablets) launch (Business Today, May 2026): https://businesstoday.in/industry/pharma/story/dr-reddys-launches-oral-semaglutide-tablets-at-rs99-per-pill-in-india-532551-2026-05-20
- Dr. Reddy's Laboratories, Company profile and product portfolio. https://www.drreddys.com
FAQ
What is Obeda?
Obeda is a generic semaglutide injection developed and marketed by Dr. Reddy's Laboratories in India. It is a once-weekly GLP-1 receptor agonist, the same class as Ozempic and Wegovy. At launch in March 2026 it was DCGI-approved for type 2 diabetes; Dr. Reddy's said it was seeking a separate weight-management approval.
How much does Obeda cost in India?
At launch in March 2026, Dr. Reddy's priced Obeda at ₹4,200 a month for both pen strengths (2 mg and 4 mg pens, each giving at least four weekly doses). Pharmacy discounts vary. Novo Nordisk cut its own Ozempic prices in India from April 2026, so check current prices with your pharmacist.
Is Obeda the same as Ozempic?
Obeda contains the same active molecule — semaglutide — as Ozempic and Wegovy. Dr. Reddy's ran its own Phase III trial in 312 people with type 2 diabetes comparing Obeda with the original medicine, which showed similar blood sugar control. Obeda is made for Dr. Reddy's in India and costs less than Novo Nordisk's brands.
How do I use the Obeda pre-filled pen?
Obeda comes as a pre-filled injection pen. You inject it once a week, on the same day each week, under the skin (subcutaneous) in the abdomen, thigh, or upper arm. Always follow your doctor's instructions for dose escalation.
Who should not take Obeda?
Obeda is not recommended for people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Consult your doctor before starting. It is not approved for use in pregnancy.
Written by
Dietician / Nutritionist
Health Content Writer
Jyothi N S is a Dietician / Nutritionist professional who contributes evidence-informed health and wellness content for Weight Easy.
View profile →Reviewed by
BHMS
Senior Medical Reviewer
Dietitian with experience in nutrition counseling, meal planning and promoting healthy lifestyles. Dedicated to help individuals achieve optimal health and well-being through personalized nutrition strategies. Skilled in providing expert guidance for managing conditions like diabetes, weight challenges and Lifestyle management.
View profile →